Ecstasy intoxication: An overlap between serotonin syndrome and neuroleptic malignant syndrome

Clinical Neuropharmacology

Volumn 19, Issue 2, 1996, Pages 157-164

  Demirkiran, Meltem ^a   Jankovic, Joseph ^a   Dean, Joel M ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b St Mary's Hospital Grand Junction   (United States)

Author keywords

3,4 Methylenedioxymethamphetamine; Ecstasy; Neuroleptic malignant syndrome; Serotonin; Serotonin syndrome

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ILLICIT DRUG;

ADULT; ARTICLE; CASE REPORT; CONFUSION; DIPLOPIA; DISORIENTATION; FEMALE; GRAND MAL SEIZURE; HUMAN; INTOXICATION; MUSCLE WEAKNESS; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTOXICITY; PRIORITY JOURNAL; RHABDOMYOLYSIS; SOMNOLENCE; VOMITING;

EID: 0029921267     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199619020-00004     Document Type: Article

References (43)

1. Rattray M. Ecstasy: towards an understanding of the biochemical basis of the actions of MDMA. Essays Biochem 1991;26:77-87.
2. Cuomo MJ, Dyment PG, Gammino VM. Increasing use of "ecstasy" (MDMA) and other hallucinogens on a college campus. J Am Coll Health 1994;42:271-4.
3. Ricaurte G, Brayn G, Strauss L, Sneiden L, Schuster C. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 1985;229:986-8.
4. McKenna DJ, Peroutka SJ. The neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine, "ecstasy." J Neurochem 1990;54:14-22.
5. Dowling GP, McDonough ET, Bost RO. "Eve" and "ecstasy." A report of five deaths associated with the use of MDEA and MDMA. JAMA 1987;257:1615-17.
6. Brown C, Osterloh J. Multiple severe complications from recreational ingestion of MDMA ("ecstasy"). [letter]. JAMA 1987;258:780-1.
7. Suarez RV, Remersema R. "Ecstasy" and sudden cardiac death. Am J Forensic Med Pathol 1988;9:339-41.
8. Chadwick IS, Linsley A, Freemont AJ, Doran B. Ecstasy, 3,4-methlenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia. J R Soc Med 1991;84:371-4.
9. Campkin NTA, Davies UM. Another death from Ecstasy. J R Soc Med 1992;85:61.
10. Fahal IH, Sallomi DF, Yaqoob M, Bell GM. Acute renal failure after ecstasy. BMJ 1992;305:29.
11. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 1992;340:384-7.
12. Screaton GR, Singer M, Cairns HS, et al. Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse [Letter]. Lancet 1992;339:677-8.
13. Hughes JC, McCabe M, Evans RJ. Intracranial haemorrhage associated with ingestion of "ecstasy." Arch Emerg Med 1993;10:372-4.
14. Logon ASC, Strickle B, O'Keefe N, Hewitson H. Survival following "ecstasy" ingestion with a peak temperature of 42°C [Letter]. Anaesthesia 1993;48:1017-18.
15. Satchell SC, Connaughton M. Inappropriate antidiuretic hormone secretion and extreme rises in serum creatinine kinase following MDMA ingestion. Br J Hosp Med 1994;51:495.
16. Walsh T, Carmichael R, Chestnut J. Anaesthetic dilemma. A hyperthermic reaction to "ecstasy." Br J Hosp Med 1994;51:476.
17. Roberts L, Wright H. Survival following intentional massive overdose of "ecstasy." J Acad Emerg Med 1994;11:53-4.
18. Battaglia G, Zackzek R, De Souza EB. MDMA effects in brain: pharmacologic profile and evidence of neurotoxicity from neurochemical and autoradiographic studies, in MDMA. In: Peroutka SJ, ed. Ecstasy and/or human neurotoxin. Norwell, MA: Kluwer, 1989:171-99.
19. Schmidt CJ, Wu L, Lovenberg W. Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analog. Eur J Pharmacol 1986;124:175-8.
20. Stone DM, Stahl DC, Hanson GR, Gibb JV. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol 1986;128:41-8.
21. 3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 1987;242:911-16.
22. Commins DL, Vosmer G, Virus RM, et al. Biochemical and histological evidence that methyl-enedioxymethamphetamine (MDMA) is toxic in the rat brain. J Pharmacol Exp Ther 1987;241: 338-45.
23. Steele TD, McCann UD, Ricaurte G. 3,4-Methylenedioxymethamphetamine (MDMA. "Ecstasy"): pharmacology and toxicology in animals and humans. Addiction 1994;89:539-51.
24. Ricaurte GA, McCann UD. Neurotoxic amphetamine analogues: effects in monkey and implications for human. Ann N Y Acad Sci 1992;648:371-82.
25. Battaglia G, Yeh SY, DeSouza EB. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav 1988;29:269-74.
26. Ali SF, Newport GD, Scallet AC, et al. Oral administration of 3,4-methylene-dioxy-methamphetamine (MDMA) produces selective serotonergic depletion in the nonhuman primate. Neurotoxicol Teratol 1993;15:91-6.
27. O'Hearn, Battaglia G, De Souza EB, et al. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 1988;8:2788-803.
28. Wilson MA, Ricauerte GA, Molliver ME. Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Neuroscience 1989;28:121-37.
29. Yamamato BK, Spanos LJ. The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur J Pharmacol 1989;148:195-203.
30. Gazzara RA, Takeda H, Cho AK, Howard SG. Inhibition of dopamine release by methylenedioxymethamphetamine is mediated by serotonin. Eur J Pharmacol 1989;168:209-17.
31. Ames D, Wirshing WC. Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome-a possible link? [Letter]. JAMA 1993;269:869.
32. Annsseau M, Reynolds CF III, Kupfer DJ, et al. Central dopaminergic and noradrenergic receptor blockade in a patient with neuroleptic malignant syndrome. J Clin Psychiatry 1984;47:320-1.
33. Tollefson GD, Garvey MJ. The neuroleptic syndrome and central dopamine metabolites. J Clin Psychopharmacol 1984;4:150-3.
34. Nisijima K, Ishiguro T. Neuroleptic malignant syndrome: a study of CSF monoamine metabolism. Biol Psychiatry 1990;27:280-3.
35. Guerra RJ, Chang SS, Romero JA. A comparison of diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychiatry 1992;53:56-62.
36. Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol 1995;18:197-214.
37. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-13.
38. Graber MA, Hoens TB, Perry PJ. Sertaline-phenelzine drug interaction: a serotonin syndrome reaction. Ann Pharmacother 1994;28:732-5.
39. Kline SS, Mauro LS, Scala-Barnett DM, Zick D. Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clin Pharmacol 1989;8:510-14.
40. Sandyk R. L-Dopa induced "serotonin syndrome" in a parkinsonian patient on bromocriptine [Letter). J Clin Psychopharmacol 1986;6:194-5.
41. Brennan D, MacManus M, Howe J, et al. "Neuroleptic malignant syndrome" without neuroleptics [Letter]. Br J Psychiatry 1988;152:578-9.
42. Halman M, Goldbloom DS. Fluoxetine and neuroleptic malignant syndrome. Biol Psychiatry 1990;28:518-21.
43. Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology 1995;45:219-23.